Status:
TERMINATED
Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer
Lead Sponsor:
Novartis Pharmaceuticals
Collaborating Sponsors:
Roche - Prof. Dr. Jens Huober et al.
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
Phase IV trial to investigate the effect of the combination of Letrozole with trastuzumab in metastatic breast cancer patients
Eligibility Criteria
Inclusion
- Postmenopausal
- Her-2 overexpression and ER and/or PgR positive
- Metastatic Breast Cancer
Exclusion
- Previous treatment with trastuzumab
- Significant Liver or renal impairment
- Erbb2 negative and/or ER and PgR negative
- Other protocol-defined inclusion / exclusion criteria may apply.
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT00171847
Start Date
March 1 2003
Last Update
March 31 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Tübingen, Germany